INTRODUCTION

Microscopic polyangiitis (MPA) is an antineutrophil cytoplasmic antibody-associated vasculitis (AAV). It is characterized by necrotizing inflammation of the small vessel. Renal impairment and alveolar hemorrhage are the most frequent manifestations. Venous system involvement has received much attention in recent years. The relationship between AAV and thromboembolic (TE) complication has been well documented. However, deep vein thrombosis is rarely the first clinical manifestation. According to literature findings, <5% of AAV have TE complication at presentation. Only one case of AAV with bilateral vein thrombosis (VT) has been reported. We report the second case of MPA presenting with renal vein thrombosis.

CASE PRESENTATION

A 33-year-old woman was presented without any past medical history. She had no prior history of deep VT. She consulted for abdominal pain and vomiting. Upper gastrointestinal endoscopy was normal. In view of the persistence of abdominal pain, an abdominal computed tomography was performed and revealed left renal VT.

The patient was therefore hospitalized for anticoagulation treatment and further investigation. Subcutaneous low molecular weight heparin was delivered. Physical examination was normal. The patient appeared euvoletic, with a blood pressure of 120/75 mm Hg. There was no synovitis, nor cutaneous rash. Her urinalysis revealed hematuria (2+) and proteinuria (2+). She had no nephrotic syndrome, and proteinuria was...
2.7 g/day. A thrombophilia workup has been performed. It included antiphospholipid antibody (lupus anticoagulant, anticardiolipin antibodies), antithrombin III, protein C, protein S, factor V Leiden mutation, and homocysteinemia. They were all negative. Laboratory findings are mentioned in Table 1.

In view of the abnormalities of her urinalysis, she underwent renal biopsy. Thirty-four glomeruli were analyzed by light microscopy, and 26 glomeruli were involved with necrotizing glomerulonephritis with cellular crescent formation. None of the glomeruli were sclerotic (crescentic class II of Berden’s classification for AAV).

No endocapillary nor mesangial hypercellularity was noted. Tubulointerstitial cross sections were normal. There was mild arterial intimal expansion, and arterioles showed mild hyalinosis; no arteritis was identified (Figure 1).

Immunofluorescence staining was negative for IgA, IgG, IgM, and C1q. Electron microscopy was not performed.

The presence of circulating antineutrophil cytoplasmic antibodies against myeloperoxidase (MPO-ANCA), in the plasma, was confirmed using enzyme-linked immunoassays (ELISA). The diagnosis of PAM was retained.

Associated alveolar hemorrhage was suspected as the patient had an unexplained anemia despite the absence of hemoptysis. Bronchoscopy with bronchoalveolar lavage was performed (BAL). The BAL fluid showed elevated numbers of hemosiderin-laden macrophages. Thoracic computed tomography was performed and confirmed the diagnosis of alveolar hemorrhage.

Pulses of methylprednisolone 1 g daily for 3 days were prescribed followed by oral Prednisone 1 mg/kg/day for 4 weeks. Doses of prednisone were then tapered down over 4 months. Monthly intravenous Cyclophosphamide at the dose of 0.75 g/m² during 6 months was also prescribed. The patient received seven plasmapheresis sessions with 60 mL/kg of replacement fluid containing albumin and fresh frozen plasma. Due to concerns of alveolar hemorrhage, anticoagulation was discontinued to prevent further exacerbation of bleeding.

During 6 months of follow-up, the patient was asymptomatic and she had normal serum creatinine level.

The patient has given his written informed consent to publish his case including publication of images.

### DISCUSSION

This observation illustrates the already known link between AAV and thromboembolic complications. There is a risk of acute venous thrombosis during AAV significantly higher than the general population (±1/1000) or among patients with chronic inflammatory disease.2

The prevalence of VT complications in AAV varies widely in the literature [Table 2]. Nevertheless, the epidemiological data in this field are still limited.

They have been initially described in pediatric patients4 and then confirmed in a large randomized study conducted by WGET Research Group.5 Alvis et al showed that patients with AAV have a risk of VTE three times higher than healthy subject.1

Chronic inflammation and other hypercoagulable states such as antiphospholipid syndrome are known to play an important role in the predisposition toward TE complications.6,7 Systemic vasculitis such as Behçet’s disease, Takayasu, and AAV is a group of chronic inflammatory disorders, and they are associated with increased risk of VTE.8

The pathophysiology of TE manifestation is well recognized in Behçet’s disease and Takayasu but it remains unclear in AAV since vascular involvement of medium or large veins is rarely observed.7,9

Numerous additional specific factors during AAV that may lead to the development of venous thrombosis were identified.

ANCA-activated neutrophil induce oxidative stress which causes endothelial dysfunction and then generate thromboses.10 Hilhorst et al compared patients with AAV in remission with sex- and age-matched healthy subject, and they found that patients with AAV have an increased endogenous

| Table 1 | Laboratory findings |
|---------|---------------------|
| **Variable** | **Result** |
| Serum hemoglobin (g/dL) | 10 |
| VGM (µ³) | 90 |
| White cell count | 6770 |
| Neutrophils | 4010 |
| Lymphocytes | 2360 |
| Platelet count | 370 000 |
| Sodium (mmol/L) | 138 |
| Potassium (mmol/L) | 4.5 |
| Urea nitrogen (mg/dL) | 9 |
| Creatinine (mg/dL) | 0.9 |
| Protein (g/dL) Total | 66 |
| Albumin | 40 |
| Thrombophilia screen | |
| Antiphospholipid antibody | Negative |
| Lupus anticoagulant | Negative |
| Anticardiolipin antibodies | Negative |
| Antithrombin III | Normal |
| Protein C | Normal |
| Protein S | Normal |
| Factor V Leiden mutation | Negative |
| Homocysteinemia | Normal |
| Urine | |
| Protein (g/day) | 2.7 |
thrombin potential and factor VII compared to healthy subjects.11

Recently, Emmi et al12 have described new mechanisms of neutrophil activation involved in thromboembolic complications during AAV. Indeed, neutrophils primed by ANCA degranulate and release extracellular nucleic acids capable of trapping bacterial agents. These extracellular neutrophil traps (NETs) are involved in thrombotic events. NETs, in turn, contain MPO and PR3 and therefore act as self-antigens.13 NETs are also able to induce thrombosis by inhibiting the tissue factor inhibitor and by activating platelets.14 Neutrophils are able to release high levels of NET expressing tissue factor during active AAVs.15

Recent studies have found a link between platelet microparticles (MPs) and activated neutrophils during AAV.15 These MPs contain inflammatory mediators and are involved in the activation and destruction of endothelial cells.16,18

Christina Wlodek and Michael Gregory Robson reported the first case of AAV presenting with renal vein thrombosis in 2012.3 The patient had a Lupus anticoagulant and anticardiolipin antibodies which is not the case of our patient.

Regarding treatment of VT in AAV, both timely immunosuppressive agents and anticoagulants are important to achieve favorable outcomes. Strategies including unfractionated heparin, low molecular weight heparin, and aspirin have been reported when facing VT in active AAV patients. Low molecular weight heparin and unfractionated heparin with a vitamin K antagonist have the same efficiency with no differences in bleeding risk. The short-term use of anticoagulations is usually about 6 months. Long-term use is often indicated for patients with recurrent or severe VT.19

The therapeutic choice for patients with AAV complicated with alveolar hemorrhage and VT is often a difficult decision. The benefits of anticoagulation treatment need to be balanced carefully against the potential risk of bleeding. The use of anticoagulation therapy may increase the risk of alveolar hemorrhage.
In our case, we decided to discontinue low molecular weight heparin due to the active alveolar hemorrhage, and no further exacerbations of VT were found. We also used plasmapheresis in order to remove ANCA and other circulatory factors such as inflammatory cytokines, complement, and coagulation factors from the systemic circulation. Hence, plasmapheresis is a logistical and important therapeutic intervention for both alveolar hemorrhage and VT.20

Regarding immunosuppressive therapy, a combination of corticosteroids and cyclophosphamide is the standard strategy of care for AAV when attempting to induce remission. High-dose prednisolone at 1 mg/kg/day should be used for at least 1 month, and methylprednisolone pulse therapy may also be used if a rapid effect is needed. In our case, we used cyclophosphamide. However, due to its side effects such as gonadal suppression and infertility, mycophenolate mofetil can be used to induce remission.20

Our observation is unique: Renal vein thrombosis revealed MPA. The patient had proteinuria without nephrotic syndrome due to the active alveolar hemorrhage, and no further exacerbations of VT were found. We also used plasmapheresis in order to remove ANCA and other circulatory factors such as inflammatory cytokines, complement, and coagulation factors from the systemic circulation. Hence, plasmapheresis is a logistical and important therapeutic intervention for both alveolar hemorrhage and VT.20

Abbreviations: EGPA, eosinophilic granulomatosis with polyangiitis; GBM, glomerular basement membrane; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; MSK, musculoskeletal; PR3, proteinase 3; RLV, renal-limited vasculitis; VT, venous thrombosis.

### 4 CONCLUSION

Venous thromboembolism is probably underestimated during AAV. The occurrence of renal vein thrombosis is exceptional. This complication may be the only manifestation of the disease. To consider the diagnosis of AAV over the occurrence of renal vein thrombosis seems unusual but can save the patient’s life. We take advantage of this article to remind that there are no current recommendations for prophylaxis, screening, or treatment of VT during AAV.

### ACKNOWLEDGMENTS

We are indebted to Drs Hiba Ghabi, Hanene Gaied, Mariem Khadhari and Taieb Ben Abdallah for their active and thoughtful contribution to the management of the patient. We also thank Dr Raja Aoudia and Dr Rim Goucha (Laboratory of renal pathology) for having performed and interpreted the patient renal biopsy. Published with written consent of the patient.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS
MJ and HG: wrote the first draft of the article. HG, MK, and TBA: critically reviewed and edited drafts. RA and RG: were the pathologists.

ETHICAL APPROVAL
The patient has given his written informed consent to publish his case including publication of images.

DATA AVAILABILITY STATEMENT
Patient data are available.

ORCID
Mouna Jerbi https://orcid.org/0000-0002-3796-1759
Hanene Gaied https://orcid.org/0000-0003-2568-9353
Rim Goucha https://orcid.org/0000-0002-1794-0774
Taieb Ben Abdallah https://orcid.org/0000-0001-9969-9824

REFERENCES
1. Berti A, Matteson EL, Crowson CS, Specks U, Corne D. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study. Mayo Clin Proc. 2018;93(5):597-606.
2. Weidner S, Hafezi-rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2006;55(1):146-149.
3. Włodek C, Robson MG. Anti-neutrophil cytoplasmic antibody vasculitis presenting with bilateral renal vein thrombosis. Clin Kidney J. 2012;5(3):229-231.
4. Von Scheven E, Lu TT, Emery HM, et al. Thrombosis and pediatric Wegener’s granulomatosis: acquired and genetic risk factors for hypercoagulability. Arthritis Rheum. 2003;49:862-865.
5. Wegener’s Granulomatosis Eranetertcet Trial (WGET) Research Group. Eranetertcet plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352(4):351-361.
6. Nagareddy P, Smyth SS. Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol. 2010;17(5):457-463.
7. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21(1):41-46.
8. Ungprasert P, Koster MJ, Thongprayoon C, Warrington KJ. Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis. Clin Rheumatol. 2016;35(11):2741-2747.
9. Balta S, Balta I, Ozturk C, Celik T, Iyisoy A. Behçet’s disease and risk of vascular events. Curr Opin Cardiol. 2016;31(4):451-457.
10. Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008;19:2421-2429.
11. Hilhorst M, Winckers K, Wilde B, van Oerle R, ten Cate H, Tervaert JW. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol. 2013;40(12):2042-2046.
12. Emmi G, Silvestri E, Squatrito D, et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015;13:15.
13. Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol. 2013;8:139-160.
14. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34-45.
15. Kambas K, Chrysanthopoulou A, Vassilopoulos D, et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis. 2014;73(10):1854-1863.
16. Niccolai E, Emmi G, Squatrito D, et al. Microparticles: bridging the gap between autoimmunity and thrombosis. Semin Thromb Hemost. 2015;41(4):413-422.
17. Hong Y, Elefteriou D, Hussain AA, et al. Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol. 2012;23(1):49-62.
18. Pitanga TN, de Aragão FL, Rocha VC, et al. Neutrophil-derived microparticles induce myeloperoxidase-mediated damage of vascular endothelial cells. BMC Cell Biol. 2014;15:21.
19. Tseng S-T, Tseng M-H, Huang J-L. Concurrent pulmonary hemorrhage and deep vein thrombosis in a child with ANCA-associated vasculitis: case report and review of literature. Pediatr Rheumatol. 2015;13:20.
20. De Sousa E, Smith R, Chaudhry A, Willcocks L, Jayne D. Venous thromboembolism with concurrent pulmonary haemorrhage in systemic vasculitis. Nephrol Dial Transplant. 2012;27(12):4357-4361.
21. Fauerschou M, Obel N, Baslund B. High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res (Hoboken). 2014;66(12):1910-1914.
22. Kang A, Antonelou M, Wong NL, et al. High incidence of arterial and venous thrombosis in antineutrophil cytoplasmic antibody–associated vasculitis. J Rheumatol. 2018;46(3):285-293.
23. Isaacs B, Gapud EJ, Antiochos B, Seo P, Geetha D. Venous thrombotic events in ANCA-associated vasculitis: incidence and risk factors. Kidney360. 2020;4(14):258-262.
24. Stassen PM, Derks RPH, Kallenberg CGM, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis—incidence and risk factors. Rheumatology (Oxford). 2008;47(4):530-534.
25. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2006;55(1):146-149.
26. Henry N, Brilland B, Wacrenier S, et al. Incidence and risk factors of venous thromboembolic events in patients with ANCA-associated vasculitis: a cohort study from the maine-anjou registry. J Clin Med. 2020;9(10):3177.

How to cite this article: Jerbi M, Ghabi H, Gaied H, et al. Deep vein thrombosis: An unusual way of revealing microscopic polyangiitis. Deep vein thrombosis in microscopic polyangiitis. Clin Case Rep. 2021;9:618–622. https://doi.org/10.1002/ccr3.3606